Beyond Blood Pressure: Expanding the Use of Renal Denervation in Diverse Pathologies

Renal denervation (RDN), initially developed for resistant hypertension, has demonstrated promising therapeutic potential beyond high blood pressure. RDN holds promise in reducing atrial fibrillation recurrence rates, particularly when combined with catheter ablation. RDN has also shown potential benefits in improving heart failure (HF) symptoms, functional capacity, and left ventricular function. Studies have documented a significant reduction in HF hospitalization rates following RDN, suggesting its role in enhancing overall patient outcomes. RDN emerged as a viable treatment option for resistant hypertension and chronic kidney disease (CKD). Studies have demonstrated its ability to effectively lower blood pressure and reduce proteinuria. Moreover, RDN is associated with improvements in renal function and overall cardiovascular outcomes in CKD patients. RDN has shown potential in improving glycemic control in metabolic syndrome patients. Some studies have documented improvements in insulin sensitivity, fasting glucose levels, and overall metabolic parameters following RDN. Additionally, RDN has been shown to significantly reduce ventricular arrhythmias in post-myocardial infarction patients. RDN can also lead to a significant improvement in sleep quality in patients with obstructive sleep apnea. While promising, further studies are needed to fully evaluate the long-term efficacy, safety, and optimal patient selection criteria for RDN in these specific clinical settings.